RESEARCH · MOTS-C · NERVOUS SYSTEM AND PAIN MODELS
MOTS-c in Nervous System Research: Hypothalamus, Memory, Brain Injury, Neurodegeneration and Pain Models
PurixLab’s MOTS-C 10mg is a research vial of the mitochondrial-derived peptide MOTS-c. Our earlier articles cover a research overview, exercise and AMPK signalling, circulating levels in humans and lung injury and sepsis models. This article turns to the nervous system: the hypothalamus, memory, neurodegeneration and brain injury models, a cluster of pain studies, and a handful of patient cohorts. One practical question runs through all of it: does peripherally administered MOTS-c reach the brain at all? These are findings from published research, almost all of it in rodents and cells; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Background
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA gene. In the discovery paper, its cellular actions inhibited the folate cycle and de novo purine biosynthesis, leading to AMPK activation, and skeletal muscle appeared to be its primary target organ [1]. Most nervous system studies build on that AMPK link, often testing whether an AMPK inhibitor blocks the effect.
The hypothalamus
The first central role came from metabolic research. In mice with mild mitochondrial ribosomal stress in hypothalamic POMC neurons (partial Crif1 deficiency), expression of beta-endorphin and MOTS-c increased, and the mice showed high-turnover metabolism and resistance to obesity. Central administration of MOTS-c reproduced the adipose phenotype, and regular moderate-intensity running stimulated hypothalamic MOTS-c expression [2]. A separate rat study delivered MOTS-c into the lateral ventricles for 14 days in 80 male rats, obese and non-obese. It reported increases in hypothalamic GnRH expression and in serum testosterone, LH and FSH, with stronger effects in non-obese animals [3]. Both studies used direct central delivery, which bypasses the question of brain entry.
Memory and the blood-brain barrier
A 2021 mouse study tested recognition memory. Central MOTS-c enhanced object and location recognition memory and ameliorated deficits induced by Aβ1-42 or LPS. The effect was blocked by the AMPK inhibitor dorsomorphin, and hippocampal AMPK phosphorylation increased while ERK, JNK and p38 did not. Crucially, the authors found that peripherally administered MOTS-c does not cross the blood-brain barrier, so they attached a cell-penetrating carrier, (PRR)5, and showed that the modified peptide given intranasally or intravenously improved memory performance [4].
Other studies report brain effects after peripheral administration, usually in models where the barrier is damaged:
- Traumatic brain injury. In male mice, injury lowered MOTS-c levels, and peripherally given MOTS-c could enter brain tissue after the injury. It improved memory, learning and motor deficits. Transcriptomics found 159 differentially expressed genes and metabolomics 491 altered metabolites, with proposed roles for reduced macrophage migration inhibitory factor and retrograde endocannabinoid signalling [5].
- Sepsis-associated brain injury. In LPS-treated mice, MOTS-c pretreatment increased survival, reduced brain inflammatory factors, reversed the increase in blood-brain barrier permeability and lowered GFAP, Iba-1 and MMP-9 [6].
- A neurodevelopmental model. In rats exposed to valproic acid before birth, systemic MOTS-c from postnatal days 21 to 46 reversed impaired sociability, repetitive behaviours and cerebellar Purkinje cell loss, but not anxiety or neocortical damage. The authors had hypothesised an indirect route via circulating BH4 and BDNF, yet no significant changes in plasma BH4 or BDNF were detected [7].
Taken together, these findings leave the access question unresolved. An injured barrier may let the peptide in, an intact one may not, and a peripheral effect could still change brain outcomes indirectly.
Neurodegeneration models
In a rotenone model of dopaminergic toxicity, rotenone shifted MOTS-c from mitochondria into the nucleus of PC12 cells, where it interacted with Nrf2 and regulated HO-1 and NQO1. MOTS-c pretreatment protected cells and rats from mitochondrial dysfunction and oxidative stress and reduced the loss of TH, PSD95 and SYP in the rat striatum [8]. Together with the Aβ1-42 memory model [4], this is the main preclinical evidence relating MOTS-c to neurodegeneration, and it rests on toxin and amyloid peptide models rather than genetic disease models.
Pain models
Pain is the most developed nervous system topic, with several models and repeated use of AMPK inhibitors:
- Formalin test. Intraperitoneal MOTS-c reduced phase 2 licking in mice, lowered pro-inflammatory cytokines, suppressed spinal ERK, JNK, p38 and c-fos activation, and the effect was attenuated by the AMPK antagonist compound C [9].
- Inflammatory pain. In formalin, capsaicin, carrageenan and complete Freund’s adjuvant models, MOTS-c reduced pain behaviours, glial activation in the spinal dorsal horn and the excitation of peripheral CGRP and P2X3 nociceptive neurons [10].
- Neuropathic pain. After spared nerve injury, MOTS-c levels in plasma and the spinal dorsal horn were lower than in controls. MOTS-c reduced allodynia; dorsomorphin blocked this but naloxone did not. The effect persisted when microglial activation was suppressed by minocycline, suggesting that spinal microglia are dispensable. Compared with morphine, spinal MOTS-c produced limited tolerance and fewer effects on gut transit, locomotion and motor coordination [11].
- Diabetic neuropathy. In streptozotocin-diabetic mice, MOTS-c reduced mechanical allodynia and thermal hyperalgesia through AMPK and PGC-1α signalling and restored spinal mitochondrial biogenesis [12].
- Bone cancer pain. Plasma MOTS-c was lower in mice with bone cancer pain; MOTS-c attenuated pain and local bone destruction, compound C blocked the effect, and chronic administration had little effect on liver, renal, lipid or cardiac function [13].
The pain papers from 2023 and 2024 share several authors [11,12,10,13], so independent replication would strengthen them. Pharmacological AMPK inhibitors are also not fully selective, and genetic AMPK models have not yet been used in this literature.
Human cohorts
Human data are observational and inconsistent:
- In a study with 32 patients per subgroup, plasma MOTS-c was lower in acute ischaemic stroke and Alzheimer’s disease than in controls, while multiple sclerosis values were similar to controls [14].
- In contrast, a study of 43 patients with relapsing-remitting multiple sclerosis and 41 controls found lower serum MOTS-c in patients, with an area under the ROC curve of 0.782 [15].
- In an Alzheimer’s study, blood and plasma MOTS-c transcript levels were reduced compared with people with subjective cognitive decline, but plasma protein concentrations did not discriminate Alzheimer’s disease from mild cognitive impairment [16].
These cohorts used ELISA, and the discordant multiple sclerosis results illustrate how assay and cohort differences can change conclusions.
What remains open
- Whether native MOTS-c crosses an intact blood-brain barrier, and in what amount.
- Whether central and peripheral sites of action can be separated in the pain models.
- Whether results hold in genetic models of neurodegeneration and in independent laboratories.
- How peptide handling, vehicle and route affect reproducibility between studies.
MOTS-C 10mg at PurixLab
MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
- Kang GM, Min SH, Lee CH, et al. Mitohormesis in Hypothalamic POMC Neurons Mediates Regular Exercise-Induced High-Turnover Metabolism. Cell Metab. 2021;33(2):334-349.e6. PubMed 33535098 · PMC7959183 · doi:10.1016/j.cmet.2021.01.003
- Ozturk Öztürk DA, Erden Y, Tekin S. Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neurosci Lett. 2024;826:137722. PubMed 38462167 · doi:10.1016/j.neulet.2024.137722
- Jiang J, Chang X, Nie Y, et al. Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates Aβ1-42- or LPS-Induced Memory Impairment through Inhibiting Neuroinflammation. ACS Chem Neurosci. 2021;12(9):1506-1518. PubMed 33861582 · doi:10.1021/acschemneuro.0c00782
- Li F, Jia Y, Fang J, et al. Neuroprotective Mechanism of MOTS-c in TBI Mice: Insights from Integrated Transcriptomic and Metabolomic Analyses. Drug Des Devel Ther. 2024;18:2971-2987. PubMed 39050800 · PMC11268520 · doi:10.2147/DDDT.S460265
- Bai Y, Wu H, Wang X, et al. A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure. Int J Neurosci. 2026;136(3):329-342. PubMed 40753494 · doi:10.1080/00207454.2025.2542883
- Güvenir Seven S, Sahin H, Erkanlı Şentürk G, et al. Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor. Mol Neurobiol. 2026;63(1):453. PubMed 41706383 · PMC12916525 · doi:10.1007/s12035-026-05741-y
- Xiao J, Zhang Q, Shan Y, et al. The Mitochondrial-Derived Peptide (MOTS-c) Interacted with Nrf2 to Defend the Antioxidant System to Protect Dopaminergic Neurons Against Rotenone Exposure. Mol Neurobiol. 2023;60(10):5915-5930. PubMed 37380822 · doi:10.1007/s12035-023-03443-3
- Yin X, Jing Y, Chen Q, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 2020;870:172909. PubMed 31926126 · doi:10.1016/j.ejphar.2020.172909
- Wang Z, Yang L, Xu L, et al. Central and peripheral mechanism of MOTS-c attenuates pain hypersensitivity in a mice model of inflammatory pain. Neurol Res. 2024;46(2):165-177. PubMed 37899006 · doi:10.1080/01616412.2023.2258584
- Jiang J, Xu L, Yang L, et al. Mitochondrial-Derived Peptide MOTS-c Ameliorates Spared Nerve Injury-Induced Neuropathic Pain in Mice by Inhibiting Microglia Activation and Neuronal Oxidative Damage in the Spinal Cord via the AMPK Pathway. ACS Chem Neurosci. 2023;14(12):2362-2374. PubMed 37285113 · doi:10.1021/acschemneuro.3c00140
- Xu L, Tang X, Yang L, et al. Mitochondria-derived peptide is an effective target for treating streptozotocin induced painful diabetic neuropathy through induction of activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator 1alpha -mediated mitochondrial biogenesis. Mol Pain. 2024;20:17448069241252654. PubMed 38658141 · PMC11113074 · doi:10.1177/17448069241252654
- Yang L, Li M, Liu Y, et al. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. Acta Biochim Biophys Sin (Shanghai). 2024;56(9):1323-1339. PubMed 38716540 · PMC11532206 · doi:10.3724/abbs.2024048
- Saçmacı H, Çakır M, Özcan SS. Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke? J Biochem Mol Toxicol. 2023;37(2):e23246. PubMed 36303331 · doi:10.1002/jbt.23246
- Tekin S, Bir LS, Avci E, et al. Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls. Cureus. 2022;14(7):e26981. PubMed 35989823 · PMC9385168 · doi:10.7759/cureus.26981
- Rodríguez-Esparragón F, Cazorla-Rivero SE, Torrealba E, et al. Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease. Int J Mol Sci. 2025;26(22):10866. PubMed 41303353 · PMC12652385 · doi:10.3390/ijms262210866